Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic

During a recent fireside chat at the Goldman Sachs (GS) Healthcare Conference in June, Moderna's President Stephen Hoge told the audience: as we've articulated, including our last R&D Day, there are really four pillars where we think our technology is mature and we're scaling, we call them modalities. The first is respiratory vaccines. The second is vaccines against other viruses, so latent viruses, and other infections. The third is our work in oncology, principally around our INT program with Merck. And t ...